Biofrontera (BFRI) FY2025 10-K Risk Factors: 11 New, 22 Dropped

What the changes say

Manufacturing equipment breakdowns, reliance on Ameluz patents, and new trade tariff vulnerabilities dominate this risk section.

What changed since the prior 10-K

New

NewRisks Related to our Products
Breakdowns , failures, or suboptimal performance of our manufacturing equipment could disrupt operations, increase costs, impair product quality, and materially and adversely affect our business, financial condition, and results of operations
NewRisks Related to Our Products
Generic versions of Ameluz may enter the market following the expiration of our patents, which may lead to significant reductions in the price of Ameluz and significant decreases in our market share
Generic versions of Ameluz could enter the market after patent expirations, reducing prices and market share, though patents protect nanoemulsions until 2027 and formulations until 2043.
NewRisks Related to Our Products
If we do not achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize our products, which would materially harm our business and we may not be able to earn sufficient revenue and cash flows to continue our operations
NewRisks Related to Our Products
Furthermore, while we take reasonable precautions to ensure the successful production of our commercial products, our contract manufacturers may experience a myriad of business difficulties (i.e., workforce instability, supply chain issues, erosion of customer base, etc.) that could impact their financial solvency
Contract manufacturers must maintain cGMP compliance and QSR standards, and their business difficulties could halt our product commercialization.
NewRisks Related to Our Products
Breakdowns, failures, or suboptimal performance of our manufacturing equipment could disrupt operations, increase costs, impair product quality, and materially and adversely affect our business, financial condition, and results of operations
Manufacturing equipment breakdowns, failures, or suboptimal performance could cause production outages, yield losses, and higher costs.
NewRisks Related to Our Products
Geopolitical instability, trade disputes, and tariffs imposed on imports could materially increase our costs, disrupt our supply chain, and adversely affect our business, financial condition, and results of operations
Tariffs on European imports and geopolitical trade disputes could increase our product costs and reduce our margins.
NewRisks Related to Our Business and Strategy
If we are unable to establish and maintain relationships with group purchasing organizations, our future revenues and/or future profitability could be jeopardized
If we fail to establish and maintain relationships with group purchasing organizations, our future revenues and profitability could be jeopardized.
NewRisks Related to Our Business and Strategy
We are subject to extensive laws and regulations. Our failure to comply with those laws and regulations could have a material adverse effect on our business, reputation, results of operations, and financial condition
We are subject to extensive healthcare, anti-kickback, and anti-corruption laws, and violations could result in significant penalties.
NewRisks Related to Our Financial Position and Capital Requirements
We have incurred losses in each year since inception. As of December 31, 2025, we had an accumulated deficit of $127.9 million
We have an accumulated deficit of $127.9 million as of December 31, 2025, and may never achieve profitability.
NewRisks Related to Clinical Trials and Regulatory Approvals of Indication Expansion
Our products may pose safety issues, cause adverse events, have side effects or have other properties that could delay or prevent the regulatory approval of additional indications, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any
Adverse events or safety issues from our products could delay clinical trials, cause restrictive labels, or trigger product liability claims.
NewRisks Related to Our Securities and Ownership of Our Common Stock
Certain provisions of our outstanding warrants, our charter documents, and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock
Warrants, charter provisions, and Delaware law contain anti-takeover provisions that could prevent a takeover and reduce our stock price.

Dropped

DroppedRisks Related to the License and Supply Agreements and Our Licensed Products
Confidentiality agreements with employees and others may not adequately prevent disclosure of our Licensors’ trade secrets and other proprietary information and may not adequately protect their intellectual property
DroppedRisks Related to the License and Supply Agreements and Our Licensed Products
The Company may be unable to effectuate a sale of Xepi® in a timely manner or receive consideration in excess of the carrying value of the asset that is currently held for sale
DroppedRisks Related to Our Business and Strategy
Biofrontera AG, as a result of its control of the manufacturing and regulatory approval of Ameluz®, may exert greater influence on the Company relative to the percentage of its ownership of the Company’s outstanding common stock
DroppedRisks Related to Our Business and Strategy
To date, we have a relatively short history of sales of our licensed products in the United States
DroppedRisks Related to Our Business and Strategy
If our Licensors face allegations of noncompliance with the law and encounter sanctions, their reputation, revenues and liquidity may suffer, and our licensed products could be subject to restrictions or withdrawal from the market
Confidentiality agreements may not adequately prevent disclosure of licensors' trade secrets.
DroppedRisks Related to Our Business and Strategy
Our licensed medical device product, the RhodoLED® lamp, is subject to extensive governmental regulation, and failure to comply with applicable requirements could cause our business to suffer
DroppedRisks Related to Our Business and Strategy
Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
DroppedRisks Related to Our Business and Strategy
Failure to comply with the United States Foreign Corrupt Practices Act or other applicable anti-corruption legislation could result in fines, criminal penalties and an adverse effect on our business
The company may be unable to sell Xepi above its $2.3 million carrying value.
DroppedRisks Related to Our Business and Strategy
Our licensed products will be subject to ongoing regulatory requirements and we may face future development, manufacturing and regulatory difficulties
Biofrontera AG may exert greater influence due to its ownership control.
DroppedRisks Related to Our Business and Strategy
Generic manufacturers may launch products at risk of patent infringement
DroppedRisks Related to Our Financial Position and Capital Requirements
We have a history of operating losses and anticipate that we will continue to incur operating losses in the future and may never sustain profitability
DroppedRisks Related to Corporate Governance, Including Being a Public Company
We have incurred, and will continue to incur, increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with our public company responsibilities and corporate governance practices
We have a relatively short history of sales of our licensed products in the United States.
DroppedRisks Related to Corporate Governance, Including Being a Public Company
We are an emerging growth company and a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
Provisions of our outstanding warrants could discourage an acquisition of us by a third party
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
Future sales of our common stock in the public market could cause our share price to fall
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline
Licensors facing legal noncompliance and sanctions could harm our licensed products.
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
Our quarterly operating results may fluctuate significantly
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
We have never paid dividends on our common stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
Our stockholder rights plan, or “poison pill,” includes terms and conditions which could discourage a takeover or other transaction that stockholders may consider favorable
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
The Rights will expire at the earlier of (a) June 30, 2026 or (b) the first day after the Company’s 2025 annual meeting, if stockholder approval has not been obtained prior to such date, the Rights will expire at such time, in each case, unless previously redeemed or exchanged by the Company
The RhodoLED lamp is subject to extensive governmental regulation.
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management
DroppedRisks Related to Our Securities and Ownership of Our Common Stock
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
Employees may engage in misconduct or noncompliance with regulatory standards.

Reworded

100% rewrittenRisks Related to Our Business and Strategy
We are subject to healthcare laws and regulations. Our failure to comply with those laws and regulations could have a material adverse effect on our results of operations and financial condition
Updated to include specific risks regarding product recalls, key personnel dependence, cyber-attacks, and foreign laws.
Was: With respect to our licensed products, we may be subject to healthcare laws, regulation and enforcement. Our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition
94% rewrittenRisks Related to Our Products
Our business depends substantially on the success of our principal product, Ameluz. If we are unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz for existing and additional indications, our business may be materially harmed
Shifted language from licensor dependencies to direct responsibilities regarding Ameluz regulatory compliance, manufacturing, and raw material sourcing.
Was: Our business depends substantially on the success of our principal licensed product Ameluz®. If we or the Ameluz Licensor are unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz® for existing and additional indications, our business may be materially harmed
66% rewrittenRisks Related to Our Securities and Ownership of Our Common Stock
We have issued several warrants, which are exercisable for our common stock, and issued Convertible Preferred Stock, which, if exercised or converted, as applicable, could substantially increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders
Updated to include Series C and Series D Convertible Preferred Stock alongside warrants, noting shares are now registered and freely tradable.
Was: We have issued several warrants, which are exercisable for our common stock, and issued Series B Convertible Preferred Stock, which, if exercised or converted, as applicable, could substantially increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders
60% rewrittenRisks Related to Our Business and Strategy
Our subsidiary and certain third-party employees are subject to foreign laws
Expanded German employment law risks to include former Biofrontera AG employees now at Biofrontera Discovery GmbH.
Was: Our subsidiary and certain third-party employees and our licensed patents are subject to foreign laws
56% rewrittenRisks Related to Our Products
If our efforts to protect the proprietary nature of our intellectual property related to our products are not adequate, we may not be able to compete effectively in our market
Shifted IP protection language from licensor-owned to company-owned patents and added risk of competitors designing around claims.
Was: If our Licensors’ efforts to protect the proprietary nature of their intellectual property related to our licensed products are not adequate, we may not be able to compete effectively in our market
51% rewrittenRisks Related to Our Business and Strategy
Even if we obtain additional regulatory approvals extending our products’ indications, they may not gain market acceptance or become widely accepted among hospitals, physicians, health care payors, patients and others in the medical community
Expanded market acceptance factors to explicitly list product labeling, side effects, and convenience for future Ameluz indications.
Was: Even if we or our Licensors obtain regulatory approvals for our licensed products, or approvals extending their indications, they may not gain market acceptance or become widely accepted among hospitals, physicians, health care payors, patients and others in the medical community
49% rewrittenRisks Related to Our Products
Competing products and future emerging products may erode sales of our products
Removed references to 'licensed' products to reflect direct ownership language across competition risks.
Was: Competing products and future emerging products may erode sales of our licensed products
43% rewrittenRisks Related to Our Business and Strategy
Third party claims of intellectual property infringement may affect our ability to sell our products and may also prevent or delay our product discovery and development efforts
Added the risk of our own ability to challenge third-party patents in the biotechnology and pharmaceutical industries.
Was: Third party claims of intellectual property infringement may affect our ability to sell our licensed products and may also prevent or delay our Licensors’ product discovery and development efforts
39% rewrittenRisks Related to Our Financial Position and Capital Requirements
There is substantial doubt about our ability to continue as a “going concern”
39% rewrittenRisks Related to Our Business and Strategy
A recall of our drug or medical device products, or the discovery of serious safety issues with our drug or medical device products, could have a significant negative impact on us
Was: A recall of our licensed drug or medical device products, or the discovery of serious safety issues with our licensed drug or medical device products, could have a significant negative impact on us
39% rewrittenRisks Related to Our Securities and Ownership of Our Common Stock
If we fail to regain and maintain compliance with applicable listing standards, our common stock and publicly-traded warrants could be delisted from Nasdaq
Was: If we fail to maintain compliance with applicable listing standards, our common stock and publicly-traded warrants could be delisted from Nasdaq
38% rewrittenRisks Related to Clinical Trials and Regulatory Approvals of Indication Expansion
We rely on third parties to conduct some of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval to extend the indications of our products
Was: We rely on third parties to conduct some of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval to extend the indications of our licensed products
34% rewrittenRisks Related to Our Business and Strategy
If we are unable to maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may be unable to generate revenue growth
Was: If we are unable to maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell our licensed products, we may be unable to generate revenue growth
28% rewrittenRisks Related to Our Securities and Ownership of Our Common Stock
Our share price may be volatile, and you may be unable to sell your shares and/or warrants at or above the offering price
27% rewrittenRisks Related to Corporate Governance, Including Being a Public Company
If we fail to maintain an effective system of internal controls, our ability to produce timely and accurate financial statements may be impaired, investors may lose confidence in our financial reporting, and the price of our common stock may decline

All 41 risk factors

Headings as the filing states them, in filing order.

Risks Related to our Products

01Breakdowns , failures, or suboptimal performance of our manufacturing equipment could disrupt operations, increase costs, impair product quality, and materially and adversely affect our business, financial condition, and results of operationsNew

Risks Related to Our Business and Strategy

02We are subject to healthcare laws and regulations. Our failure to comply with those laws and regulations could have a material adverse effect on our results of operations and financial condition100% rewritten
13Insurance coverage and medical expense reimbursement may be limited or unavailable in certain market segments for our products, including with respect to future indications of our products, which could make it difficult for us to sell our products
14In the United States and certain other countries, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably
15If we are unable to maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may be unable to generate revenue growth34% rewritten
16If we are unable to establish and maintain relationships with group purchasing organizations, our future revenues and/or future profitability could be jeopardizedNew
17The United States market size for Ameluz for the treatment of AK may be smaller than we have estimated
18Even if we obtain additional regulatory approvals extending our products’ indications, they may not gain market acceptance or become widely accepted among hospitals, physicians, health care payors, patients and others in the medical community51% rewritten
19We are subject to extensive laws and regulations. Our failure to comply with those laws and regulations could have a material adverse effect on our business, reputation, results of operations, and financial conditionNew
20A recall of our drug or medical device products, or the discovery of serious safety issues with our drug or medical device products, could have a significant negative impact on us39% rewritten
21We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may be unable to successfully implement our business strategy
22We will need to grow the size of our organization and we may experience difficulties in managing this growth
23Our business and operations would suffer in the event of system failures or cyber-attacks
24If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
25Our subsidiary and certain third-party employees are subject to foreign laws60% rewritten
26Third party claims of intellectual property infringement may affect our ability to sell our products and may also prevent or delay our product discovery and development efforts43% rewritten
27The results of our R&D efforts are uncertain and there can be no assurance they will enhance the commercial success of our products

Risks Related to Our Products

03Generic versions of Ameluz may enter the market following the expiration of our patents, which may lead to significant reductions in the price of Ameluz and significant decreases in our market shareNew
04Our business depends substantially on the success of our principal product, Ameluz. If we are unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz for existing and additional indications, our business may be materially harmed94% rewritten
05If we do not achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize our products, which would materially harm our business and we may not be able to earn sufficient revenue and cash flows to continue our operationsNew
06Furthermore, while we take reasonable precautions to ensure the successful production of our commercial products, our contract manufacturers may experience a myriad of business difficulties (i.e., workforce instability, supply chain issues, erosion of customer base, etc.) that could impact their financial solvencyNew
07Breakdowns, failures, or suboptimal performance of our manufacturing equipment could disrupt operations, increase costs, impair product quality, and materially and adversely affect our business, financial condition, and results of operationsNew
08If our efforts to protect the proprietary nature of our intellectual property related to our products are not adequate, we may not be able to compete effectively in our market56% rewritten
09We are and have been involved in intellectual property lawsuits related to our products and we may become involved in similar suits in the future, which could be expensive, time-consuming and unsuccessful
10Our international dealings may pose currency risks, which may adversely affect our operating results and net income
11Competing products and future emerging products may erode sales of our products49% rewritten
12Geopolitical instability, trade disputes, and tariffs imposed on imports could materially increase our costs, disrupt our supply chain, and adversely affect our business, financial condition, and results of operationsNew

Risks Related to Our Financial Position and Capital Requirements

28There is substantial doubt about our ability to continue as a “going concern”39% rewritten
29We have incurred losses in each year since inception. As of December 31, 2025, we had an accumulated deficit of $127.9 millionNew
30Our existing and any future indebtedness could adversely affect our ability to operate our business

Risks Related to Clinical Trials and Regulatory Approvals of Indication Expansion

31Delay or termination of planned clinical trials for expanding the indications of Ameluz would result in unplanned expenses and significantly and adversely impact our remaining developmental activities and potential commercial prospects with respect to, and ability to generate revenues from, such indications
32Our products may pose safety issues, cause adverse events, have side effects or have other properties that could delay or prevent the regulatory approval of additional indications, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if anyNew
33The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for additional indications of our products on a timely basis or at all, our business could be substantially harmed
34We rely on third parties to conduct some of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval to extend the indications of our products38% rewritten

Risks Related to Corporate Governance, Including Being a Public Company

35If we fail to maintain an effective system of internal controls, our ability to produce timely and accurate financial statements may be impaired, investors may lose confidence in our financial reporting, and the price of our common stock may decline27% rewritten

Risks Related to Our Securities and Ownership of Our Common Stock

36Our share price may be volatile, and you may be unable to sell your shares and/or warrants at or above the offering price28% rewritten
37If we fail to regain and maintain compliance with applicable listing standards, our common stock and publicly-traded warrants could be delisted from Nasdaq39% rewritten
38We have issued several warrants, which are exercisable for our common stock, and issued Convertible Preferred Stock, which, if exercised or converted, as applicable, could substantially increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders66% rewritten
39Future sales and issuances of our common stock or rights to purchase our common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the stock price of our common stock to decline
40Certain provisions of our outstanding warrants, our charter documents, and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stockNew
41Many of the warrants to purchase shares of our common stock are accounted for as a warrant liability and recorded at fair value with changes in fair value each period reported in earnings, which may have an adverse effect on the market price of our common stock

Other Biofrontera 10-Ks

FY2024 10-K risk factors
52 risks
Substantial doubt exists regarding the company's ability to continue as a going concern, with accumulated deficits reaching $117.4 million by the end of 2024.
Filed Mar 20, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.